NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.

doi:10.1186/s13058-024-01823-8

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.

Breast cancer research : BCR - 22 Apr 2024

Jacobs Samuel A, Wang Ying, Abraham Jame, Feng Huichen, Montero Alberto J, Lipchik Corey, Finnigan Melanie, Jankowitz Rachel C, Salkeni Mohamad A, Maley Sai K, Puhalla Shannon L, Piette Fanny, Quinn Katie, Chang Kyle, Nagy Rebecca J, Allegra Carmen J, Vehec Kelly, Wolmark Norman, Lucas Peter C, Srinivasan Ashok, Pogue-Geile Katherine L

Abstract excerpt

BACKGROUND: We previously reported our phase Ib trial, testing the safety, tolerability, and efficacy of T-DM1 + neratinib in HER2-positive metastatic breast cancer patients. Patients with ERBB2 amplification in ctDNA had deeper and more durable responses. This study extends these observations with in-depth analysis of molecular markers and mechanisms of resistance in additional patients. METHODS: Forty-nine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Breast Neoplasms

Share to Circulating Tumor DNA

Share to Neoplasm Metastasis

Share to Quinolines

Share to Receptor, ErbB-2

Share to Trastuzumab

Source

Open in PubMed Open full text

Identifiers

PMID: 38650031
DOI: 10.1186/s13058-024-01823-8
PMCID: PMC11036567

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.PMID 38650031Read ↗

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancerSemantic proximity Read ↗

Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trialsSemantic proximity Read ↗

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.Semantic proximity Read ↗

Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial.Semantic proximity Read ↗

Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancerSemantic proximity Read ↗

ctDNA Analysis in ERBB2 -Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway TrialSemantic proximity Read ↗

Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer.Semantic proximity Read ↗

A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutationSemantic proximity Read ↗

Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response.Semantic proximity Read ↗

Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.Semantic proximity Read ↗

Evaluating the investigational drug landscape for ESR1-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.Semantic proximity Read ↗

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.